Beyond the above-described telitacicept, several other monoclonal antibodies target the BAFF/APRIL complex: atacicept, an anti-BAFF antibody, surprisingly exacerbated MS disease activity in a phase 2 study [201], but may be beneficial in NMOSD because of a different pathophysiology. This evidence concerns the gene TNFSF13B and myeloid sarcoma.